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The incidence of distant metastases is higher in the tumours with low oxygen pressure than in those with high oxygen
pressure. It is well known that hypoxia induces the transcription of various genes involved in angiogenesis and anaerobic
metabolism necessary for the growth of tumour cells in vivo, suggesting that hypoxia may also induce the transcription of
metastasis-associated genes. We sought to identify the metastasis-associated genes differentially expressed in tumour cells
under hypoxic conditions with the use of a DNA microarray system. We found that hypoxia enhanced the expression of
autocrine motility factor mRNA in various cancer cells and also enhanced the random motility of pancreatic cancer cells.
Autocrine motility factor inhibitors abrogated the increase of motility under hypoxic conditions. In order to explore the roles
of hypoxia-inducible factor-1a, we established hypoxia-inducible factor-1a-transfectants and dominant negative hypoxia-
inducible factor-1a-transfectants. Transfection with hypoxia-inducible factor-1a and dominant-negative hypoxia-inducible
factor-1a enhanced and suppressed the expression of autocrine motility factor/phosphohexase isomerase/neuroleukin mRNA
and the random motility, respectively. These results suggest that hypoxia may promote the metastatic potential of cancer cells
through the enhanced autocrine motility factor/phosphohexase isomerase/neuroleukin mRNA expression and that the
disruption of the hypoxia-inducible factor-1 pathway may be an effective treatment for metastasis.
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As metastasis is the major cause of death in cancer patients,
control of metastasis is most important in the therapies for cancer
patients. In order to control metastasis, we need to understand
the details of metastatic process that is now thought to take
multiple steps. Although a variety of factors have been documen-
ted to play important roles in the metastatic steps (Poste and
Fidler, 1980; Liotta, 1986, 1988; Nicolson, 1988), many factors
are yet to be elucidated. Several clinical investigations demon-
strated that patients with hypoxic tumours had poor prognoses
and that the incidence of distant metastases was higher in the
tumours with low oxygen pressure than in those with high oxygen
pressure (Gatenby et al, 1988; Brizel et al, 1996; Hockel et al,
1998; Rofstad, 2000). These studies suggest that the tumour cells
exposed to hypoxia at the primary tumour sites acquire aggressive
properties including metastatic potential more than the well-
oxygenated tumour cells do. In fact, recent reports have demon-
strated that hypoxia enhances the expression of vascular
endothelial growth factor (VEGF) and interleukin-8 (IL-8) in
tumour cells, resulting in an increase of metastatic potential (Claf-
fey and Robinson, 1996; Shi et al, 1999; Biroccio et al, 2000).
However, it remains poorly understood how hypoxia promotes
tumour cells’ metastatic potential.
When tumour cells are exposed to hypoxia, hypoxia-inducible
factor-1 (HIF-1), which is a transcription factor composed of
HIF-1a and HIF-1b subunits (Wang et al, 1995; Wang and Semen-
za, 1996), is activated and then it promotes the transcription of
several genes such as glucose transporters, glycolytic enzymes,
and angiogenic factors (Dang and Semenza, 1999). A recent report
demonstrates that human common cancer cells over-express
hypoxia-inducible factor-1a (HIF-1a) in vivo and that the expres-
sion of HIF-1a is associated with metastasis (Zhong et al, 1999).
Furthermore, inﬁltration of endothelial cells, which involves
various factors, is enhanced when tumour tissues are in hypoxia-
induced angiogenesis. These reports have prompted us to hypothe-
sise that hypoxia may also promote the invasion and metastasis of
tumour cells by promoting the expression of metastasis-associated
genes in addition to angiogenic factors through the activation of
HIF-1a. As hypovasculature is an outstanding characteristic of
pancreatic cancers with high invasiveness and metastatic potential
(Raijiman and Levin, 1995) and most pancreatic cancer cells
over-express HIF-1a protein (Akakura et al, 2001), we speculate
that pancreatic cancer cells may be exposed to severe hypoxia in
vivo and that pancreatic cancers express higher levels of meta-
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www.bjcancer.comstasis-associated genes in addition to angiogenic factors than well-
oxygenated tumour cells do. Therefore we examined the expression
of more than 9000 mRNAs in a pancreatic cancer cell line under
hypoxic and non-hypoxic conditions with the use of a DNA micro-
array system and compared them to identify the metastasis-
associated genes induced by hypoxia.
We found that autocrine motility factor (AMF)/phosphohexose
isomerase (PHI)/neuroleukin (NL) mRNA was expressed more
highly in the cells under hypoxic conditions than under non-hypoxic
conditions. In this study, we examined the expression of AMF/PHI/
NL mRNA in a variety of cancer cell lines and the random motility
of apancreatic cancercelllineunderhypoxicand non-hypoxic condi-
tions, because AMF/PHI/NL was reported to stimulate random
motility (Liotta et al, 1986). Furthermore, we established HIF-1a-
transfectantsanddominant-negative HIF-1a-transfectants andexam-
inedtheirexpressionofAMF/PHI/NL mRNAandrandommotilityin
order to determine the possible role of HIF-1a in the AMF/PHI/NL
mRNA expression and random motility promoted by hypoxia.
MATERIALS AND METHODS
Cell lines
Pancreatic ductal adenocarcinoma cell lines (PCI-6, PCI-10, PCI-19,
PCI-43 and PCI-66 cells) were established from surgically resected
pancreatic cancer tissues. These cell lines were kindly supplied from
Dr Hiroshi Ishikura (The First Department of Pathology, Hokkaido
University School of Medicine, Japan) and maintained in DMEM/
F12 medium supplemented with 10% foetal calf serum (FCS).
TAOV (ovarian cancer), TTOV (ovarian cancer), HepG2 (hepato-
ma), PC-6 (lung cancer), MiaPaca-2 (pancreatic cancer), BxPC-3
(pancreatic cancer) and KM-12 (colon cancer) cells were main-
tained in DMEM medium supplemented with 10% FCS.
DNA microarray analysis
Total RNA was extracted with the use of TRIZOL Reagent (Life
Technologies, Tokyo, Japan) from the PCI-10 cells that had been
incubated for 24 h under non-hypoxic and hypoxic conditions.
The incubation under hypoxic condition (1% O2) was done in a
hypoxic chamber gassed with 95% N2 and 5% CO2 (Wakenyaku
Co. Ltd., Tokyo, Japan). mRNA was puriﬁed from the total RNA
with the use of a Quickprep mRNA puriﬁcation kit (Amersham
Pharmacia Biotech, Tokyo, Japan). Differentially expressed genes
were screened with the use of a DNA microarray system, UniGEM
human (Kurabo Industries Ltd, Osaka, Japan). We deﬁned the
genes expressed at more than two-fold higher levels under hypoxic
conditions than under non-hypoxic conditions as possible hypoxia-
inducible genes in this study.
Establishment of HIF-1a-transfectants and dominant
negative HIF-1a-transfectants
Establishment of HIF-1a-transfectants was previously reported
(Akakura et al, 2001). A cDNA for dominant negative HIF-1a
(dnHIF-1a) lacking both the DNA binding and transactivation
domains of HIF-1a was ampliﬁed from reverse transcription (RT)
products of mRNAs puriﬁed from the PCI-10 cells and cloned into
PCR4-TOPO (Invitrogen, Carlsbad, CA, USA). PCR primers for
dominant negative HIF-1a were selected as previously described
(Halterman et al, 1999) (forward, ccgctcgagaccatgcgaaggaaagaatctg;
reverse, ggggtacctcatttgtcaaagaggctact). Plasmids were recovered,
puriﬁed and sequenced with a DyeDeoxy Terminator kit (Perkin-
Elmer, Urayasu, Japan) on an ABI 377 automated sequencer
(Applied Biosystems, Urayasu, Japan) in the condition described
in the manufacturer’s protocol. Cloned fragments were recovered
from the vectors and ligated into PcDNA3.1+ (Invitrogen, Carlsbad,
CA, USA). PCI-43 cells were transfected with the expression vector
for dnHIF-1a with the use of Lipofectamine (Life Technologies,
Tokyo, Japan). Transfectants were cloned by a limiting dilution
method after the selection with G-418 at 800 mgm l
71. The trans-
fectants were maintained in the presence of 400 mgm l
71 of G-418.
FACS analysis
Cells were stained with anti-AMFR antibody (rat monoclonal anti-
body, IgM) (Niinaka et al, 1998) for 1 h and then stained with a
second anti-rat Ig antibody for 1 h. Expression of AMFR proteins
was quantiﬁed with the use of FACScaliber (Becton Dickinson,
Mountain View, CA, USA).
Northern blot analysis
Northern blot analysis was performed by the method described
previously (Choi et al, 2000). Total RNA (20 mg) was separated
by electrophoresis in 1.2% denaturing formaldehyde-agarose gels.
The RNA was transferred to nylon membrane (Hybond N
+, Amer-
sham) overnight by capillary elution and UV cross-linked. After
prehybridisation of the blots for 1–2 h at 428C in hybridisation
buffer (56SSPE, 56Denhardt’s solution, 1% SDS, 50% Forma-
mide and 0.1 mg ml
71 of denatured salmon sperm DNA), the
membrane was hybridised overnight at 428C with the cDNA probes
for AMF and AMF receptor (AMFR). The probed membrane was
then washed and exposed to radiographic ﬁlm. cDNA fragments
for AMF and AMF receptor (AMFR) were ampliﬁed by RT–
PCR, cloned into a TA cloning vector, puriﬁed from the vector
and then used as probes for Northern blot analysis. PCR primers
were as follows: AMF forward, gcttgaccctcaacaccaac; reverse,
gaagtgctggtccatccagt; AMFR forward, caggaggaagtgagccagtc; reverse,
agcttgctgcctaaccactc.
Phagokinetic track assay
Phagokinetic track assay was performed according to the method
reported by Albrecht-Buehler (1977). Brieﬂy, gold particle suspen-
sion was prepared by mixing 18 ml of 14.5 mM AuCl4 solution and
5 ml of 36.5 mM Na2CO3 solution with 11 ml double-distilled
water followed by heating to boiling point and adding 1.8 ml of
0.1% formaldehyde. Two ml of gold particle suspension was laid
on the 18618 mm-square glass coverslips coated with 0.1% bovine
serum albumin. The particle-coated coverslips were placed in
35 mm plastic dishes containing DMEM/F-12 medium supplemen-
ted with 5% FCS. Cells were seeded in the dishes and incubated for
24 h. After incubation, the coverslips were removed and ﬁxed in
10% formaldehyde solution for 30 min and mounted on micro-
scope slides. Phagokinetic track areas of more than 20 cells that
were randomly selected were observed with the use of a microscope
analyser (Cosmo zone R500, Nikon, Japan). The experiments were
done under hypoxic (1% O2 per 5% CO2) and non-hypoxic condi-
tions (20% O2 per 5% CO2). In some experiments, supernatant of
the pancreatic cancer cells PCI-10 cultured in hypoxia was added
in the dishes at 0, 12.5, 25, 50 and 100%. PHI inhibitors described
in the previous report (Watanabe et al, 1996), erythrose 4-phos-
phate (E4P) and 6-phosphogluconic acid (6PGA) (Sigma) were
added into the dishes at 10, 100 and 1000 mM.
Statistical analysis
Statistical analysis was done by the Mann–Whitney test.
RESULTS
Differentially expressed genes under hypoxic conditions
We deﬁned the genes expressed at more than two-fold higher
levels under hypoxic conditions than under non-hypoxic condi-
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expected, mRNAs for glycolytic enzymes and angiogenic factors
were expressed at higher levels under hypoxic conditions than
under non-hypoxic conditions. In the glycolytic enzymes, we
found that phosphohexose isomerase (PHI) mRNA was expressed
at a two-fold higher level under hypoxic conditions than under
non-hypoxic conditions. A recent report has demonstrated that
AMF, which was originally identiﬁed as a molecule stimulating
directional motility (chemotaxis) and random motility (chemo-
kinesis) of melanoma cells (Liotta et al, 1986), was identical to
PHI/NL (Watanabe et al, 1996). As AMF/PHI/NL secreted by
tumour cells acts as a chemokinetic factor (random motility-
stimulating factor) in an autocrine fashion, we focused on this
molecule that could promote the metastatic potential under
hypoxic conditions.
Expressions of AMF/PHI/NL and AMFR in a variety of
cancer cells
We then examined the expression of AMF/PHI/NL mRNA in
several cancer cell lines, including PCI-10 cells used in the
DNA microarray analysis, before and after exposure to hypoxia
in order to deﬁne whether the enhanced expression of AMF/
PHI/NL mRNA in hypoxia was common in a variety of cancer
cells. Figure 1A shows the expression of AMF/PHI/NL mRNA
in the pancreatic cancer cell lines (PCI-6, PCI-10, PCI-19,
PCI-43, PCI-66, MiaPaca-2 and BxPC-3), colon cancer cell line
(KM-12), lung cancer cell line (PC-6), hepatoma cell line
(HepG2) and ovarian cancer cell lines (TAOV and TTOV).
All the cell lines expressed AMF/PHI/NL mRNA at higher levels
under hypoxic conditions than under non-hypoxic conditions,
indicating that the increased expression of AMF/PHI/NL mRNA
under hypoxic conditions was common in a variety of cancer
cells. Next we examined the expression of AMFR. All the cell
lines examined, especially PCI-10 cells used for the examination
of motility, expressed AMFR mRNA and protein (Figure 1B,C),
suggesting that the AMF/PHI/NL could stimulate the random
motility of the cells in an autocrine fashion.
Expression of AMF/PHI/NL mRNA in HIF-1a-transfectants
and dominant-negative HIF-1a-transfectants
Figure 2A shows the expression of AMF/PHI/NL mRNA in the
HIF-1a-transfectants and the vector-transfectant under non-
hypoxic conditions. The expression of AMF/PHI/NL mRNA was
higher in the HIF-1a-transfectants than in the vector-transfectant.
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Figure 1 Expression of AMF/PHI/NL and AMFR mRNAs. (A) AMF/PHI/NL mRNA expression. RNAs were extracted from the cells incubated under
non-hypoxic (N) and hypoxic (H) conditions (20% and 1%, respectively) for 24 h and then Northern blot analysis was performed. (B) AMFR mRNA ex-
pression. RNAs were extracted from the cells incubated under non-hypoxic (N) for 24 h and then Northern blot analysis was performed. A representative
result of two different experiments is shown. (C) FACS analysis of AMFR expression. Cells were stained with anti-AMFR antibody (rat monoclonal antibody,
IgM) for 1 h and then stained with second anti-rat Ig antibody for 1 h. A representative result of two different experiments is shown.
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(dnHIF-1a) mRNA. The dnHIF-1a-transfectants but not the
vector-transfectant expressed the truncated dnHIF-1a mRNA in
addition to the endogenous HIF-1a mRNA. Expression of AMF/
PHI/NL mRNA was enhanced after exposure to hypoxia in the
vector-transfectant and the parent cells but not in the dnHIF-1a-
transfectants (Figure 2C). These results suggested that hypoxia
might enhance the expression of AMF/PHI/NL mRNA through
the activation of HIF-1.
Random motility
As shown in Figure 3A, the random motility of PCI-10 cells
increased under hypoxic conditions by more than four-fold
compared with that under non-hypoxic conditions. Furthermore,
the random motility of the HIF-1a-transfectants under non-
hypoxic conditions was higher than that of the vector-transfectant
(Figure 3B). Figure 3C shows the random motility of the dnHIF-
1a-transfectants under hypoxic and non-hypoxic conditions. The
random motility of the vector-transfectant but not of the dnHIF-
1a-transfectants was enhanced under hypoxic conditions. These
results in combination with the changes in the AMF/PHI/NL
mRNA expression suggested that the random motility was closely
correlated with the levels of AMF/PHI/NL mRNA expression.
Next, as AMF/PHI/NL has been reported to act in an autocrine
fashion, we examined the effects of the supernatant of PCI-10 cells
cultured under hypoxic conditions on their motility. Figure 3D
shows that the supernatant enhanced the random motility of
PCI-10 cells under non-hypoxic conditions in a dose-dependent
manner, indicating that the random motility-stimulating activity
in the supernatant stimulated it in an autocrine fashion. In order
to determine whether the presumed random motility-stimulating
factor in the supernatant was identical to AMF/PHI/NL, we exam-
ined the effects of two carbohydrate phosphates, 6-
phosphogluconic acid (6PGA) and erythrose 4-phosphate (E4P),
which have been reported to inhibit the PHI enzymatic activity
and the AMF-induced cell motility (Watanabe et al, 1996). Figure
3D shows that 6PGA and E4P almost completely abrogated the
motility-stimulating activity of the supernatant. Figure 3E shows
that 6PGA and E4P directly reduced the random motility of
PCI-10 cells enhanced under hypoxic conditions.
DISCUSSION
A number of reports have demonstrated that the probability of
distant metastases correlates with oxygen pressure in the tumour
tissues (Gatenby et al, 1988; Brizel et al, 1996; Hockel et al,
1998; Rofstad, 2000), suggesting that hypoxia may promote meta-
static potential. However, it remains poorly understood how
hypoxia promotes the metastatic potential of tumour cells. In this
study, we clearly demonstrated that hypoxia enhanced the AMF/
PHI/NL mRNA expression in a variety of cancer cells and it also
enhanced the random motility in an autocrine fashion. In accor-
dance with our results, a recent report demonstrated that AMF/
PHI/NL was identiﬁed as a hypoxia-inducible gene by a representa-
tional difference analysis using mRNA extracted from hypoxic and
normoxic Capan-2, a human pancreatic cancer cell line (Yoon et
al, 2001). However, it was not determined whether the enhanced
expression of AMF/PHI/NL resulted in the enhanced motility. As
hypoxia is frequently observed in tumour tissues in vivo (Guillemin
and Krasnow, 1997; Blancher and Harris, 1998), we suspected that
AMF/PHI/NL might be expressed in various cancer cells in vivo.I n
accordance with this speculation, previous reports demonstrated
that the expression of AMF/PHI/NL was found in human colorec-
tal, bladder, oesophageal and gastric cancers and that the
expression of AMF/PHI/NL correlated with the disease progression
(Watanabe et al, 1991; Nabi et al, 1992). Furthermore, we found
that AMF/PHI/NL was expressed also in the tumour cells of human
pancreatic cancers in vivo (data not shown). Recently we have
reported that most pancreatic cancer cells, which are known to
show high invasiveness and high metastatic potential in vivo,
over-expressed HIF-1a proteins constitutively (Akakura et al,
2001). Those results in combination with the ﬁndings demon-
strated in this study suggest that high expression of AMF/PHI/
NL may be attributable to the high invasiveness and high meta-
static potential of pancreatic cancers.
It is well-known that metastasis requires coordinated activation
of various factors involved in proliferation, motility, cell-to-cell
and cell-to-substrate contacts, degradation of extracellular matrix,
inhibition of apoptosis, and adaptation to an inappropriate tissue
environment (Poste and Fidler, 1980; Liotta et al, 1986). Our
DNA microarray study showed that mRNA expressions of various
angiogenic factors and glycolytic enzymes were enhanced in hypox-
ia in accordance with the previous reports (Vaupel et al, 1989;
Semenza, 2000). Increased expression of angiogenic factors under
hypoxic conditions enhances the angiogenesis that supports the
survival and growth of tumour cells in the metastatic sites as well
as in the primary sites (Claffey and Robinson, 1996; Rofstad and
Danielsen, 1999). Likewise increased expression of glycolytic
enzymes supports the survival and growth of tumour cells under
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Figure 2 Expression of AMF/PHI/NL mRNA in the transfectants: (A)
Northern blot analysis of AMF/PHI/NL mRNA in the HIF-1a-transfectants
(PCI-10/H2 and PCI-10/H3) and vector-transfectant (PCI-10/V2) under
non-hypoxic conditions. AMF/PHI/NL mRNA expression in PCI-10 cells
under non-hypoxic (N) and hypoxic (H) conditions were shown as con-
trols. (B) Northern blot analysis of dominant negative HIF-1a (dnHIF-1a)
mRNA in the transfectants. (C) Northern blot analysis of AMF/PHI/NL
mRNA expression in the dnHIF-1a -transfectants (PCI-43/dnH3 and PCI-
43/dnH7) and the vector-transfectant (PCI-43/vV3) under non-hypoxic
(N) and hypoxic (H) conditions. RNAs were extracted from the cells incu-
bated under non-hypoxic (N) and hypoxic (H) conditions for 24 h and
then Northern blot analysis was performed.
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these angiogenic factors and glycolytic enzymes induced by hypoxia
could enhance the metastasis in cooperation with AMF/PHI/NL.
Namely, hypoxia promotes the inﬁltration of endothelial cells into
tumour tissues in its inducing angiogenesis; the hypoxia may also
induce the activation of various factors other than angiogenic
factors and AMF/PHI/NL in cancer cells. We now search the possi-
ble metastasis-associated genes, which should have hypoxia-
responsive elements (HRE) in the promoter region.
All together, our present results provide a new insight into the
mechanisms and a possible means for control of metastasis. We
now propose that the enhancement of metastatic potential may
be one of hypoxic responses of tumour cells exposed to hypoxia.
The ﬁndings of dominant-negative HIF-1a-transfectants suggest
that the disruption of the HIF-1 pathway may be an effective treat-
ment for metastasis, in addition to the treatment of primary
tumours through the inhibition of various genes necessary for
the growth and metastasis of tumour cells in vivo, in accordance
with the previous report (Kung et al, 2000).
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Figure 3 Random motility: Data present the mean+s.d. of three different experiments. (A) Random motility of the PCI-10 cells under hypoxic and
normoxic conditions. *P50.01; signiﬁcantly different compared with the relative motility of the PCI-10 cells under normoxic conditions. (B) Random mo-
tility of the HIF-1a-transfectants under non-hypoxic conditions. *P50.01; signiﬁcantly different compared with the vector control. (C) Random motility of
the dnHIF-1a-transfectants and the vector-transfectant under hypoxic and non-hypoxic conditions. *P50.05; signiﬁcantly different compared with the re-
lative motility of the PCI-43 cells under normoxic conditions. (D) Random motility of PCI-10 cells under normoxic conditions in the presence or absence of
the supernatant of PCI-10 cells cultured under hypoxic conditions. *P50.01, **P50.05; signiﬁcantly different compared with the relative motility of PCI-10
cells under normoxic conditions in the absence of supernatant. {P50.05; signiﬁcantly different compared with the relative motility of PCI-10 cells in the
presence of 100% supernatant. (E) Random motility of the PCI-10 cells under hypoxic conditions in the presence of AMF/PHI-inhibitors. *P50.01; signiﬁ-
cantly different compared with the relative motility of PCI-10 cells under normoxic conditions. {P50.01; signiﬁcantly different compared with the relative
motility of PCI-10 cells under normoxic conditions in the absence of inhibitor.
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